was read the article
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 218 | 156 | 374 |
| 2025 11 | 205 | 214 | 419 |
| 2025 10 | 109 | 157 | 266 |
| 2025 9 | 181 | 179 | 360 |
| 2025 8 | 269 | 178 | 447 |
| 2025 7 | 208 | 52 | 260 |
| 2025 6 | 223 | 30 | 253 |
| 2025 5 | 210 | 20 | 230 |
| 2025 4 | 24 | 9 | 33 |
Follow this link to access the full text of the article
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 218 | 156 | 374 |
| 2025 11 | 205 | 214 | 419 |
| 2025 10 | 109 | 157 | 266 |
| 2025 9 | 181 | 179 | 360 |
| 2025 8 | 269 | 178 | 447 |
| 2025 7 | 208 | 52 | 260 |
| 2025 6 | 223 | 30 | 253 |
| 2025 5 | 210 | 20 | 230 |
| 2025 4 | 24 | 9 | 33 |
Supplementary Fig. 1. Swimmers’ plot of cabozantinib treatment: The swimmer’s plot illustrates the duration of cabozantinib treatment for each patient, represented by individual bars. The length of each bar corresponds to the time on treatment, with markers indicating key events such as determine response, progression, and death. Patients who are alive denoted with arrows at the end of the bar. Colors within the bars represent viral hepatitis infection, including HBV, HCV, co-infection, and non-viral infection.
Supplementary Fig. 2. Liver function monitoring: (A) The proportional changes in ALBI grade following cabozantinib treatment at baseline, and after 4 and 8 weeks was shown. (B) The ALBI score showed a significant deterioration at 4 weeks following the initiation of treatment (baseline vs. 4 weeks: −2.30 ± 0.64 vs. −2.14 ± 0.73; p = 0.003) but remained stable with no significant change at 8 weeks (4 weeks vs. 8 weeks: −2.14 ± 0.73 vs. −2.04 ± 0.76; p = 0.159).
Supplementary Fig. 1. Swimmers’ plot of cabozantinib treatment: The swimmer’s plot illustrates the duration of cabozantinib treatment for each patient, represented by individual bars. The length of each bar corresponds to the time on treatment, with markers indicating key events such as determine response, progression, and death. Patients who are alive denoted with arrows at the end of the bar. Colors within the bars represent viral hepatitis infection, including HBV, HCV, co-infection, and non-viral infection.
Supplementary Fig. 2. Liver function monitoring: (A) The proportional changes in ALBI grade following cabozantinib treatment at baseline, and after 4 and 8 weeks was shown. (B) The ALBI score showed a significant deterioration at 4 weeks following the initiation of treatment (baseline vs. 4 weeks: −2.30 ± 0.64 vs. −2.14 ± 0.73; p = 0.003) but remained stable with no significant change at 8 weeks (4 weeks vs. 8 weeks: −2.14 ± 0.73 vs. −2.04 ± 0.76; p = 0.159).